The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

The investigational mRNA-1010 influenza vaccine has undergone extensive clinical evaluation in a series of trials involving ...

The Cleveland Clinic notes that there is no cure for measles, and measles just has to "run its course." However, the best ...

Researchers conducted the IMPROVE trial to evaluate whether a 3-week pause in BTK inhibitor use would improve immunity after COVID-19 booster vaccination without negatively affecting disease control ...

Immunizing mice with an edited Lyme disease-causing bacterial protein effectively protected them against the disease.

QIV was immunogenic against all 4 vaccine strains and 87.0%, 88.6%, 69.8% and 97.9% of children had postvaccination titers of ≥1:40 against A/H1N1, A/H3N2, B/Victoria and B/Yamagata, respectively.

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

One of the requirements of graduate school in the US stumped me: an immunization certificate for the MMR vaccine ...

AIM's mRNA technology platform is not only fast but also effective. Specifically for the recently approved mRNA shingles vaccine, results from testing units indicated that this product's specific ...

Officials recommend that children get their first dose of the measles-mumps-rubella (MMR) vaccine between 12 and 15 months of age. Two doses of the vaccine are 97% effective against the measles virus.